Abstract: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.

Abstract: The invention relates to a composition having antimicrobial and hygroscopic properties and the composition comprises a carboxylic acid compound as well as at least one C3-C6 diol and at least one C8-C12 diol. The composition of the invention may be used for cleansing, disinfection, surface treatment, impregnation and for antimicrobial treatment. The composition is particularly useful for treatment of fungal infections of the nail (onychomycosis).

Abstract: A composition comprising: at least one compound of the chemical structure: [ H x ? O ( x - 1 ) 2 ] ? Z y wherein x is and odd integer ?3; y is an integer between 1 and 20; and Z is one of a monoatomic ion from Groups 14 through 17 having a charge value between ?1 and ?3 or a polyatomic ion having a charge between ?1 and ?3; or Z?—Hx?Ox?-y? wherein x? is and integer greater than 3 y? is an integer less than x?; and Z? is one of a monoatomic cation, a polyatomic ion or a cationic complex; and at least one of a humectant emollient or carrier.

Abstract: A well treatment material for introduction into a subterranean formation is provided. The well treatment material can include a biocide collected onto a sorbent. The biocide can be capable of being desorbed at a generally constant rate over an extended period of time into the subterranean formation. The biocide can be an oxidizing biocide or a non-oxidizing biocide. The sorbent material can include one or more of an absorbent material and an adsorbent material. The biocide can be chlorine dioxide. The sorbent can be one or more of silica gel and graphite.

Abstract: A method of synthesizing silica nanoparticles. The method includes hydrolyzing a silica precursor to form a plurality of monomers, each monomer of the plurality comprising a microwave reactive silicon species. The plurality of monomers is irradiated by an energy source configured to generate microwave frequency energy. Irradiation cases the plurality of monomers polymerize into a silica nanoparticle.

Abstract: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to a composition or kit of parts comprising an inhibitor of IRS-1 and an inhibitor of the VEGF pathway and to the use thereof for treating an angiogenic disease.

Abstract: An aqueous biocidal composition comprising a mixture of hydrochloric acid (HCl), urea, and sodium hypochlorite (NaOCl) at acidic pH, a method for manufacturing the composition and a biocidal technology for treating industrial water.

Abstract: A method for using urea sulfate as an anti-microbial agent, anti-mold agent, anti-fungal agent, and pH adjusting compound with the benefit of adding nitrogen and sulfur to the food supply. Urea sulfate provides a fundamental contribution to feed hygiene, as it suppresses the growth of mold and thus restricts the potential effect of mycotoxins. Consequently, feed safety is improved by adding this compound.

Abstract: The present invention provides synergistic combinations of monochlorourea with other biocides for controlling microbial growth in aqueous systems. It also provides synergistic combinations of dimethyl monochlorourea with other biocides for controlling growth in aqueous systems. The synergistic combinations of monochlorourea and dimethyl monochlorourea with other biocides allows for the reduced use of total biocides to provide control of microbial growth in aqueous systems.

Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.

Abstract: Discovery of a new Bax isoform, Bax?2, in cancer cell lines and primary tumors is described. The Bax?2 isoform resulted from combination of Bax microsatellite mutation and alternative splicing Bax exon 2. It is also discovered that Bax?2 renders cancer cells sensitive to certain chemotherapeutic drugs that target caspase 8. Also provided are methods for treating colorectal cancer by administering to a colorectal cancer patient a chemotherapeutic agent that is capable of activating caspase 8, wherein the patient contains a cancer cell that expresses a Bax?2 protein (SEQ ID NO. 2).

Abstract: Disclosed herein are methods and compositions for treating autism. Disclosed herein are methods and compositions for treating an autism spectrum disorder.

Abstract: Topical dermatological preparations including one or more lipodissolving, lipolytic, or adipocyte-disrupting substances for treatment of localized adiposity can include carbamide peroxide and a terpene such as d-limonene. In some embodiments, the preparations can include carbamide peroxide as a first component and, as a second component, at least one peppermint oil terpene, peppermint oil, or a compound isolated or derived from peppermint oil.

Abstract: A topical wound treatment composition comprises a hydrogen peroxide generator; alkaline powder; not more than 5 percent by weight of water; additional topical active agent if desired, and emollient (preferably hygroscopic emollient) to balance. When topically applied to a wound and water from the surrounding environment diffuses into the composition, the hydrogen peroxide generator and/or the alkaline compound diffuse into one another, causing a chemical reaction that generates treatment-effective amounts of oxygen to occur. The oxygen can then diffuse out of the composition and aid in wound treatment or healing.

Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.

Abstract: The present invention provides an aqueous composition and its use for dissolving blood clots in vivo or in clinical or research samples in vitro, said composition comprising at least one chaotropic agent, at least one chelating agent that complexes iron if the chaotropic agent does not complex iron and at least one surface-active emulsifier, the composition being buffered near pH 7.4. The process of dissolving the clot with the aqueous composition is advantageous because it is simple, inexpensive, rapid and can be applied in a variety of contexts, including basic research and clinical situations.

Abstract: Compositions and methods for urea silicone gels for treating skin conditions that may benefit from barrier protection and from urea silicone gel ability to return water balance to the skin are disclosed. Skin conditions that may be treated with urea silicone gel may be excessive dryness, insect bites, keloids and scars, among others. Disclosed urea silicone gel may include micronized urea USP, an anhydrous silicone base, and a PEG ointment base, among other ingredients. Anhydrous silicone base may include Amazonian oils such as pracaxi oil and seje oil, which are rich in oleic, linolenic, linoleic acids, and sterols, particularly beta-sitosterol and stigmasterol that may increase skin permeability to urea. PEG ointment base may be water-washable and includes meadowsweet extract. Additionally, PEG urea silicone gel may provide occlusion, and may maintain a moist environment within the skin condition which allows optimal healing. Pain also may be decreased by maintaining a moist environment.

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1 and R2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.

Abstract: A synergistic composition, or the use of that composition in the manufacture of a medicament, or a method of treatment including the use of that composition, for the treatment of hair loss and baldness, for combined, sequential or simultaneous administration, in any form, via any biological route. In its optimal embodiment the composition consists, in the form of a lotion: 1600-2400 IU/mL Vitamin A Palmitate, 0.64%-0.96% Thiamine Hydrochloride, 0.64%-0.96% Pyridoxine Hydrochloride, 4.8%-7.2% Niacinamide, 2.85%-5.2% D-Panthenol, 1.6%-2.4% L-Arginine, 3.6%-4.4% Methyl Sulphonyl Methane (MSM), 0.08%-0.12% Ginger Oil, 0.08%-0.12% Cinnamon Oil, 0.0996%-0.1494% Oleoresin Capsicum, 1.3%-1.95% Magnesium, 2.4%-3.6% Zinc, 0.192%-0.288% Manganese, 2.6%-3.9% Urea, 2.4%-3.6% Sodium Glycerophosphate, 4.8%-7.2% L-Lysine HCl, plus Preservatives, Co-solvent (Propylene Glycol), Fragrances, Anti-Oxidant, Cooling agent (Menthol), Emulsifier, and Vehicle (Purified water).

Abstract: Methods and compositions that down regulate the activity of orexins to treat panic disorder and panic-like responses associated with hypercapnic conditions are disclosed.

Abstract: Melanocortin receptor modulators, processes for preparing them and use thereof in human medicine and cosmetics are described. Melanocortin receptor modulators corresponding to formula (I): compositions containing them, processes for their preparation and their use in pharmaceutical or cosmetic compositions are also described.

Abstract: The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms.

Abstract: Disclosed are methods of maintaining fertility or treating retained placenta, reproductive tract infection, or reproductive tract inflammation in an animal by administering carbamide peroxide to the reproductive tract of the animal. The carbamide peroxide administration removes placental remains on the uterine wall, protects against or treats reproductive tract infection, and protects against or treats reproductive tract inflammation such as metritis, and thereby maintains fertility in the animal.

Abstract: The invention relates to the field of medicament use, in particular to the clinical use of carbamide peroxide injection series for virus inactivation in the treatment of blood vessel plaque, leukemia, AIDS and hepatitis, etc. The invention utilizes the affinity of photosensitizers to blood vessel plaque focus, leukemia cells, tumor, and/or virus, which is several times higher than that to normal tissues, so as to destroy focus cells or virus by generating sufficient singlet oxygen (1O2) under the effect of a method using laser, X-ray, ultrasound and medicament, etc., while in condition of using carbamide peroxide injection series. The effects for treating the above diseases are achieved efficiently without serious side effects to the normal human tissues and organs.

Abstract: The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin and particular regimens for administering this combination. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.

Abstract: The invention describes nanotextured super hydrophobic coatings that contain active agents which can elute from the coating over a period of time.

Abstract: The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1-R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R1 and R3 is each independently C1-C20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

Abstract: Method of identifying compounds that modulate intermolecular interactions between a target protein and a modifier are disclosed. Pharmaceutical composition comprising compounds that inhibit intermolecular interactions between a target protein and a modifier are disclosed. Methods of treating individual suffering from inflammatory conditions, undesirable immune responses, immunological conditions and bacterial infections are disclosed.

Abstract: An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficulty soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, “Entrapped Drug Reservoir System”.

Abstract: The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.

Abstract: A process for solubilizing hydrophobic active ingredients in aqueous medium, which comprises using, as an assistant, at least one hyperbranched polymer (A) which is obtainable by reacting at least one hyperbranched polymeric compound having at least one primary or secondary amino group per molecule (a), selected from (a1) hyperbranched polyamides and (a2) hyperbranched polyureas, with (b) at least one mono-, di- or oligosaccharide.

Abstract: The present invention provides novel heterocyclic urea compounds having useful antibacterial activity, pharmaceutical compositions comprising one or more of these compounds, methods of making the same, and methods of using the same.

Abstract: Methods for treating disorders of the eye and/or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I as set forth herein. For ophthalmic applications, the compound may be delivered by intravitreal injection such that the compound causes vitreal liquefaction, posterior vitreoretinal detachment and other affects.

Abstract: This invention relates to the field of topical treatments for infections such as nail infections, particularly fungal infections of the nail commonly referred to as onychomycosis. Particularly, the invention relates to novel compositions containing peroxide for the treatment of such nail infections and other infections.

Abstract: Methods of treating a subject having, or at risk of having, a myeloproliferative disorder are provided according to embodiments of the present invention which include administering a therapeutically effective amount of an arachidonate 5-lipoxygenase (5-LO) inhibitor to the subject. Combinations of therapeutic agents are administered according to embodiments of the present invention. In some embodiments, two or more 5-LO inhibitors are administered to a subject to treat a myeloproliferative disorder. In further embodiments, at least one 5-LO inhibitor and at least one additional therapeutic agent are administered to a subject to treat a myeloproliferative disorder. Methods of inhibiting leukemia stem cells are provided according to embodiments of the present invention which include contacting leukemia stem cells with an effective amount of an arachidonate 5-lipoxygenase inhibitor.

Abstract: The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.

Abstract: The present invention provides acyclic, geminal-dinitro organic compounds, methods of synthesizing the compounds, pharmaceutical compositions, therapeutic methods, and medical kits for treating various conditions using such compounds and pharmaceutical compositions. The compounds and compositions are useful in the treatment of cancer.

Abstract: This invention relates to the field of topical treatments for infections such as nail infections, particularly fungal infections of the nail commonly referred to as onychomycosis. Particularly, the invention relates to novel compositions containing peroxide for the treatment of such nail infections and other infections.

Abstract: A keratolytic emollient, which includes urea, mineral oil, and paraffin wax.

Abstract: Method of single step electrochemical generation of chlorinated urea, chlorinated dimethylurea and other chlorourea derivatives is disclosed. The chlorinated species are generated in situ and upon demand and can be used for microbial control in industrial water treatment.

Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.

Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.

Abstract: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.

Abstract: A process for reducing curl and/or frizziness of hair comprising: (a) providing a composition for reducing curl and/or frizziness of hair, said composition comprising, in a cosmetically acceptable carrier: (i) at least one non-hydroxide base; (ii) at least one protein denaturant different from (a)(i); (iii) at least one alkoxysilane comprising at least one solubilizing functional group; and (iv) optionally, at least one fatty substance; (b) contacting the hair with the composition in (a) to form treated hair; (c) optionally, rinsing the composition in (a) from the treated hair; (d) optionally, contacting the treated hair with a conditioning agent; (e) smoothing the treated hair using a combination of heat and means for physically smoothing hair to form smoothed hair; (f) optionally, shampooing the smoothed hair; and (g) rinsing the smoothed hair.

Abstract: Composition and method for treating and/or preventing biological contamination using a biocide composition comprising at least one quaternary ammonium compound and urea. The method includes drying urea, and thereafter combining at least one quaternary ammonium compound and urea and may produce a potent biocide composition that is stable and able to chemically treat biological contamination in a variety of difficult to reach locations. Uses of the composition are also described.

Abstract: The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.

Abstract: The present invention relates to hydrogel particles coated with lipid, which are made from dispersing hydrogel particles in an organic solvent in which lipids are dissolved, and to a method for manufacturing same. Unlike the existing method for manufacturing hydrogel core vesicles, the present invention can effectively manufacture same by using an emulsification method, without involving the steps of chemical treatment of the surface of hydrogels or dilution, thereby facilitating mass production and preventing the decrease of drug encapsulation efficiency.

Abstract: The invention provides a process for manufacturing biocidal compositions containing bromourea derivatives, including the reaction of salts or adducts of the urea derivatives with an oxidizer.

Abstract: Provided, among other things, is a delivery module for a non-greasy, water-based urea composition comprising: an aerosol delivery device; within the aerosol delivery device, the urea composition comprising 20% or more urea by weight, non-greasy lipophilic component(s), and a frothing agent, the urea composition having a viscosity low enough to support aerosol delivery, and the urea composition effective to form a foam upon propellant-driven aerosol delivery; and within the aerosol delivery device, a propellant.